The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...
Find insight on AstraZeneca, Celltrion and more in the latest Market Talks covering the Health Care sector.
Astrazeneca shares rose nearly 1% following unexpectedly positive interim results from a Phase III trial of its breast cancer drug Camizestrant. The study revealed that patients with hormone ...
New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...
"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...
dampening down the autoimmune response that leads to neuronal damage in MS. AstraZeneca's BTK inhibitor Calquence is the first drug in the class to be approved in the US for first-line treatment ...
Just days after dosing its first patient in a Duchenne muscular dystrophy trial, US biotech PepGen has pushed the button on an initial public offering (IPO). The Boston-based company has filed ...